

- genetic variants and environmental factors. *Mol Psychiatry* 2012; 17: 624–633
2. Licinio J, Wong M-L (eds): *Pharmacogenomics: The Search for Individualized Therapies*, Hoboken, NJ, Wiley-Blackwell, 2009
  3. LLerena A, Dorado P, O’Kirwan F, et al: Lower frequency of CYP2C9\*2 in Mexican-Americans compared to Spaniards. *Pharmacogenomics J* 2004; 4:403–406
  4. Licinio J, Dong C, Wong M-L: Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. *Arch Gen Psychiatry* 2009; 66:488–497
  5. United States Census Bureau: <http://www.census.gov/>

**Ma-Li Wong, M.D.**  
**Chuanhui Dong, Ph.D.**  
**Deborah L. Flores, M.D.**  
**Monika Ehrhart-Bornstein, Ph.D.**

**Stefan Bornstein, M.D., Ph.D.**  
**Mauricio Arcos-Burgos, M.D., Ph.D.**  
**Julio Licinio, M.D.**

*From the Mind and Brain Theme, South Australian Health and Medical Research Institute, and the Department of Psychiatry, Flinders University School of Medicine, Adelaide, Australia; the Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami; the Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, Calif.; Medical Clinic III, Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany; and the John Curtin School of Medical Research, Australian National University, Canberra, Australia.*

*The authors’ disclosures accompany the original article.*

*This reply was accepted for publication in January 2015.*

*Am J Psychiatry* 2015; 172:396–398; doi: 10.1176/appi.ajp.2015.14101348r

## Disclosure of Editors’ Financial Relationships

The *American Journal of Psychiatry* requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

**Robert Freedman, M.D.**, reports no financial relationships with commercial interests.

**David A. Lewis, M.D.**, currently receives investigator-initiated research support from Pfizer and in 2012–2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, and Concert Pharmaceuticals.

**Robert Michels, M.D.**, reports no financial relationships with commercial interests.

**Daniel S. Pine, M.D.**, reports no financial relationships with commercial interests.

**A. John Rush, M.D.**, has served as a consultant for Eli Lilly, Santium, and Takeda; and has received compensation from Brain Resource, Inc., Guilford Press, Lundbeck, and Medavante.

**Susan K. Schultz, M.D.**, has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company.

**Carol A. Tamminga, M.D.**, has received research support from Sunovion and travel funds from Autifony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck.